Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Sulindac for Patients With AML
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01843179
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: CarmustineDrug: EtoposideDrug: CytarabineDrug: MelphalanBiological: PegfilgrastimBiological: 19-28z T CELLSProcedure: Autologous Stem Cell Transplantation
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01840566
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- Drug: azacitidineDrug: cytarabineDrug: mitoxantrone hydrochlorideOther: laboratory biomarker analysis
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT01839240
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT01838395
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Pure Erythroid Leukemia (M6b)Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableUntreated Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Monocytic Leukemia (M5b)
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT01831232
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Brentuximab Vedotin + Re-induction Chemotherapy for AML
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01830777
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myelomonocytic Leukemia (M4)Adult Pure Erythroid Leukemia (M6b)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Erythroleukemia (M6a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)
- Interventions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2023-02-03
- Target Recruit Count
- 55
- Registration Number
- NCT01822015
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Untreated Adult Acute Myeloid Leukemia
- Interventions
- Drug: CytarabineDrug: Daunorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: NilotinibOther: Pharmacological Study
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 34
- Registration Number
- NCT01806571
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: IdarubicinOther: Laboratory Biomarker AnalysisDrug: Vorinostat
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 754
- Registration Number
- NCT01802333
- Locations
- 🇺🇸
Flaget Memorial Hospital, Bardstown, Kentucky, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Erythroleukemia (M6a)Childhood Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)
- Interventions
- Drug: mitoxantrone hydrochlorideDrug: cytarabineProcedure: peripheral blood stem cell transplantationOther: laboratory biomarker analysis
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT01801046
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.